Note: The following is edited from a press release from Bioverativ. Read the full press release in its entirety here.
Bioverativ Inc.,Â a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced findings from a novel imaging study investigating extravascular distribution of factor IX therapies, including its leading extended half-life therapy, ALPROLIX®Â [Antihemophilic Factor IX (Recombinant), Fc Fusion Protein]. The preclinical study showed ALPROLIX had a higher level of extravascular distribution and retention in certain joint areas when compared with conventional factor IX and a glycoPEGylated factor IX analog. The study was conducted in collaboration with Invicro, LLC, a leading imaging services provider, and is being presented Dec. 9, 2017 at the 59thÂ Annual Meeting of the American Society of Hematology.